Intended for healthcare professionals

The British Association of Dermatologist Biologics and Immunomodulators Register (BADBIR): an update

The original British Association of Dermatologists Biologic Interventions Register (BADBIR) was set up in 2007 to evaluate the long-term safety of biologic therapies for psoriasis1 . Data collected at baseline include current and previous treatments for psoriasis, disease severity, comorbid conditions and treatments, patientreported measures and lifestyle questions.

Patients are then followed up every six months for the first three years with data collected on changes in therapy, safety events, psoriasis disease severity and updated patient-reported questionnaires. After three years, data collection changes to annual follow-up with patient-reported measures and lifestyle questions no longer captured. BADBIR also benefits from linkage to national cancer and death registries, and inpatient admission registries in England, Scotland and Wales to maximise the capture of safety events. The register was powered to discern the risk of non-melanoma skin cancer in psoriasis patients treated with biologic therapies and was designed as a web-based entry using a comparator cohort of patients on conventional systemic therapies such as methotrexate, ciclosporin and acitretin.

Dermatology in practice 2020; 26(2): 10–12
To continue reading this article, please sign in or register.